Vox Markets Logo

Physiomics' chemotherapy dosage tool may have "nearer term revenue potential"

09:26, 14th May 2019
Anita Riotta
Company News
TwitterFacebookLinkedIn

Through an Innovate UK-funded grant project,  Physiomics (PYC) has designed a tool to help doctors discern the appropriate amount of chemotherapy for a particular patient.

Physiomics completed the tool last month with the aid of £68,000 from the Innovate UK grant. 

Normally, doctors administer a similar dosage to patients, but when considering the variability of each patient’s response to the drug this can often lead to under- or over-dosing of the chemotherapy. 

However, Physiomics’ new tool uses blood tests to give clinicians a better insight into the toxicity and efficacy of a given dose, therefore allowing them to optimize treatment for the individual patient. 

And, the company believes there is “nearer term revenue potential” than might be expected from a medical device likely to be subjected to further clinical validation, arguing it could be used earlier in research settings. 

Moreover, the tool is likely to reduce costs and health detriments, such as toxicity, associated with over-dosing chemotherapy as well as avoid the decreased efficacy that comes with under-dosing. 

The company hopes to begin the commercialization process quickly and is currently approaching potential strategic partners, clinical collaborators and grant providers to that end.

For more news and updates on Physiomics: FOLLOW

TwitterFacebookLinkedIn

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Recent Articles
Watchlist